Indian Economy News

Mankind Pharma joins hands with Denovo Sciences for AI-powered drug discovery

Mankind Pharma has partnered with Denovo Sciences to launch an Artificial Intelligence (AI)-driven drug discovery programme, marking a significant step in advancing technology-led pharmaceutical research and development in India. The collaboration aims to accelerate early-stage drug discovery by reducing development timelines, improving the quality of lead candidates and identifying the most promising drug molecules with greater precision. The partnership will combine Mankind Pharma's research and development infrastructure, experimental capabilities and clinical validation expertise with Denovo Sciences' proprietary AI platform. Operating under a human-in-the-loop model, the programme will integrate AI-generated molecular analysis with continuous scientific validation, enabling researchers to make more informed decisions throughout the drug discovery process. The initiative is expected to reduce the time and resources spent on compounds with a lower probability of clinical success while improving overall research efficiency.

The collaboration reflects the growing adoption of Artificial Intelligence across India's pharmaceutical sector to strengthen innovation and improve healthcare outcomes. By leveraging computational technologies at the earliest stages of drug development, the programme is expected to accelerate discovery cycles and support the development of differentiated, effective and accessible therapies. The partnership also reinforces India's expanding capabilities in AI-enabled life sciences research, complementing the country's strong pharmaceutical manufacturing and research ecosystem. Increased adoption of advanced digital technologies such as AI is expected to enhance research productivity, foster innovation and strengthen India's position as a global hub for pharmaceutical research, biotechnology and next-generation healthcare solutions.

Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.